These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20803482)

  • 1. Links between analysis of surrogate endpoints and endogeneity.
    Ghosh D; Elliott MR; Taylor JM
    Stat Med; 2010 Dec; 29(28):2869-79. PubMed ID: 20803482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the relationship between the causal-inference and meta-analytic paradigms for the evaluation of surrogate endpoints.
    Van der Elst W; Molenberghs G; Alonso A
    Stat Med; 2016 Apr; 35(8):1281-98. PubMed ID: 26612787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An information-theoretic approach for the evaluation of surrogate endpoints based on causal inference.
    Alonso A; Van der Elst W; Molenberghs G; Buyse M; Burzykowski T
    Biometrics; 2016 Sep; 72(3):669-77. PubMed ID: 26864244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A reflection on the possibility of finding a good surrogate.
    Alonso A; Meyvisch P; Van der Elst W; Molenberghs G; Verbeke G
    J Biopharm Stat; 2019; 29(3):468-477. PubMed ID: 30686082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new proportion measure of the treatment effect captured by candidate surrogate endpoints.
    Kobayashi F; Kuroki M
    Stat Med; 2014 Aug; 33(19):3338-53. PubMed ID: 24782344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods for the analysis of multiple endpoints in small populations: A review.
    Ristl R; Urach S; Rosenkranz G; Posch M
    J Biopharm Stat; 2019; 29(1):1-29. PubMed ID: 29985752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A reflection on the causal interpretation of individual-level surrogacy.
    Alonso A; Van Der Elst W; Molenberghs G; Florez AJ
    J Biopharm Stat; 2019; 29(3):529-540. PubMed ID: 30773114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel procedures for validating surrogate endpoints in clinical trials.
    Cleophas TJ; Zwinderman AH; Chaib AH
    Curr Clin Pharmacol; 2007 May; 2(2):123-8. PubMed ID: 18690859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.
    Tanaka S; Matsuyama Y; Ohashi Y
    Stat Med; 2017 Aug; 36(19):2963-2977. PubMed ID: 28485043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of matched pair designs with two binary endpoints.
    Jiang Y; Xu J
    Stat Methods Med Res; 2017 Dec; 26(6):2526-2542. PubMed ID: 26294329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A maximum entropy approach for the evaluation of surrogate endpoints based on causal inference.
    Alonso A; Van der Elst W; Molenberghs G
    Stat Med; 2018 Dec; 37(29):4525-4538. PubMed ID: 30141219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical challenges in the evaluation of surrogate endpoints in randomized trials.
    Molenberghs G; Buyse M; Geys H; Renard D; Burzykowski T; Alonso A
    Control Clin Trials; 2002 Dec; 23(6):607-25. PubMed ID: 12505240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative methods to evaluate trial level surrogacy.
    Abrahantes JC; Shkedy Z; Molenberghs G
    Clin Trials; 2008; 5(3):194-208. PubMed ID: 18559408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive cluster level surrogacy in the presence of interference.
    Gabriel EE; Follmann DA
    Biostatistics; 2020 Apr; 21(2):e33-e46. PubMed ID: 30247535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials.
    Sofeu CL; Rondeau V
    PLoS One; 2020; 15(1):e0228098. PubMed ID: 31990928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Odds ratio for 2 × 2 tables: Mantel-Haenszel estimator, profile likelihood, and presence of surrogate responses.
    Banerjee B; Biswas A
    J Biopharm Stat; 2014; 24(3):649-59. PubMed ID: 24697719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.
    Conlon AS; Taylor JM; Elliott MR
    Biostatistics; 2014 Apr; 15(2):266-83. PubMed ID: 24285772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surrogate markers and joint models for longitudinal and survival data.
    Taylor JM; Wang Y
    Control Clin Trials; 2002 Dec; 23(6):626-34. PubMed ID: 12505241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inference for Surrogate Endpoint Validation in the Binary Case.
    Bebu I; Mathew T; Agan B
    J Biopharm Stat; 2015; 25(6):1272-84. PubMed ID: 25616958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing temporal agreement between central and local progression-free survival times.
    Zeng D; Cornea E; Dong J; Pan J; Ibrahim JG
    Stat Med; 2015 Feb; 34(5):844-58. PubMed ID: 25393731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.